Comparative Pharmacology
Head-to-head clinical analysis: BLISOVI 24 FE versus ENSKYCE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BLISOVI 24 FE versus ENSKYCE.
BLISOVI 24 FE vs ENSKYCE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination of ethinyl estradiol and drospirenone; primarily suppresses gonadotropins (FSH, LH) via negative feedback, preventing ovulation. Drospirenone has anti-mineralocorticoid and anti-androgenic activity.
ENSKYCE (fospropofol disodium) is a prodrug of propofol. It is hydrolyzed by alkaline phosphatases to release propofol, which acts as a positive allosteric modulator of GABA-A receptors, enhancing chloride conductance and producing sedation and anesthesia.
One tablet orally once daily for 24 weeks, followed by placebo tablets for 4 weeks; each tablet contains 0.15 mg levonorgestrel and 0.03 mg ethinyl estradiol for 21 days, then 0.01 mg ethinyl estradiol for 3 days, then 2 tablets of 75 mg ferrous fumarate for 5 days.
2 g IV every 8 hours over 5 hours on days 1-3 of each 21-day cycle
None Documented
None Documented
Drospirenone: 25-33 hours; Ethinyl estradiol: 13-24 hours; steady-state achieved after 10 days.
12 hours (terminal); allows once-daily dosing in most patients
Renal: 30-40% as drospirenone metabolites, 20-30% as ethinyl estradiol metabolites; fecal: 40-50% as drospirenone metabolites, 30-40% as ethinyl estradiol metabolites; biliary: minimal.
Renal: ~70% unchanged; Biliary/Fecal: ~20% as metabolites
Category C
Category C
Oral Contraceptive
Oral Contraceptive